Randomized phase II study of dual epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without irinotecan as second-line therapy in patients with metastatic colorectal cancer.

Abstract

e15037Background: Median PFS for second line treatment of mCRC with anti-EGFR ranges from 4.5-5.5 months. Preclinical data support the hypothesis that dual blockade of the EGFR with a monoclonal an...